Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia

OBJECTIVE: To determine whether children aged 3-59 months with mild or non-symptomatic human immunodeficiency virus (HIV) infection and WHO-defined severe pneumonia have a higher failure rate than do HIV-uninfected children when treated with the standard WHO treatment of parenteral penicillin or ora...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeena Prakash (Author), Thea Donald M (Author), MacLeod William B (Author), Chisaka Noel (Author), Fox Matthew P (Author), Coovadia HM (Author), Qazi Shamim (Author)
Format: Book
Published: The World Health Organization, 2006-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b8081b24f0d74d168a0af6c81c4cdeb9
042 |a dc 
100 1 0 |a Jeena Prakash  |e author 
700 1 0 |a Thea Donald M  |e author 
700 1 0 |a MacLeod William B  |e author 
700 1 0 |a Chisaka Noel  |e author 
700 1 0 |a Fox Matthew P  |e author 
700 1 0 |a Coovadia HM  |e author 
700 1 0 |a Qazi Shamim  |e author 
245 0 0 |a Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia 
260 |b The World Health Organization,   |c 2006-01-01T00:00:00Z. 
500 |a 0042-9686 
520 |a OBJECTIVE: To determine whether children aged 3-59 months with mild or non-symptomatic human immunodeficiency virus (HIV) infection and WHO-defined severe pneumonia have a higher failure rate than do HIV-uninfected children when treated with the standard WHO treatment of parenteral penicillin or oral amoxicillin. METHODS: This study was a planned sub-analysis of a randomized trial of 3-59-month-old children presenting with WHO-defined severe pneumonia (the APPIS study). We included two sites with high HIV prevalence in Durban, South Africa and Ndola, Zambia. Primary outcome measures were clinical treatment failure at day 2 and day 14. CLINICALTRIALS.GOV IDENTIFIER: CT00227331http://www.clinicaltrialsgov/show/NCT00227331). FINDINGS: Of the 523 children enrolled, HIV status was known for 464 participants; 106 (23%) of these were infected with HIV. By day 2, 57 (12.3%) children had failed treatment and 110 (23.7%) failed by day 14. Twenty (18.9%) HIV-infected children failed by day 2 compared with 37 (10.3%) uninfected children (adjusted odds ratio (OR) 2.07; 95% confidence interval (CI): 1.07-4.00). Thirty-four (32.1%) HIV-infected children failed treatment by day 14 compared with 76 (21.2%) uninfected children (adjusted OR 1.88; 95% CI: 1.11-3.17). Analysis stratified by age showed that the greatest differential in treatment failure at day 2 and day 14 occurred in the children aged 3-5 months. CONCLUSIONS: HIV-infected children with severe pneumonia fail WHO-standard treatment with parenteral penicillin or amoxicillin at day 2 and day 14 more often than do HIV-uninfected children, especially young infants. Standard case management of acute respiratory infection (ARI) using WHO treatment guidelines is inadequate in areas of high HIV prevalence and reappraisal of empiric antimicrobial therapy is urgently needed for severe pneumonia associated with HIV-1. 
546 |a EN 
690 |a Pneumonia/drug therapy 
690 |a HIV infections 
690 |a Infant 
690 |a Child 
690 |a Penicillins 
690 |a Amoxicillin 
690 |a South Africa 
690 |a Zambia 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Bulletin of the World Health Organization, Vol 84, Iss 4, Pp 269-275 (2006) 
787 0 |n http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000400010 
787 0 |n https://doaj.org/toc/0042-9686 
856 4 1 |u https://doaj.org/article/b8081b24f0d74d168a0af6c81c4cdeb9  |z Connect to this object online.